Day One Biopharmaceuticals, Inc. Quality Score

DAWN

⊜ Compare

Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Growth

Cash Flow Growth

0/100

Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution

0/100

57.6%

Heavy dilution above 5%

Capital Structure

100/100

-$438M

Net cash position, no leverage concern

2022

$342M

$813000

2023

$366M

$408000

2024

$532M

$3.00M

2025

$441M

$3.00M

CashDebt

Return on Capital

0/100

-21.3%

Below 8%, may not cover cost of capital

Customize WeightsPremiumAdjust metric weights to match your investment style.Upgrade

SourceQuality score computed from the 10-Q filed 24 Feb 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DAWN

CompareIntrinsic value

HRTXHeron Therapeutics Inc.

$0.30+7.14%36

KPTIKaryopharm Therapeutics Inc.

$0.07-17.16%15

NUVBNuvation Bio Inc.

$4.73+0.85%10

ELTPElite Pharmaceuticals Inc.

$0.25+3.29%89

ZVRAZevra Therapeutics, Inc.

$11.17+8.87%83

ABUSArbutus Biopharma Corporation

$4.06+4.64%60

LFVNLifeVantage Corporation

$5.97+3.65%73

MGNXMacrogenics Inc.

$2.31-0.86%36

Spot a number that looks wrong? Check it in DAWN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DAWN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.